ALLHAT: Lisinopril vs Chlorthalidone vs Amlodipine
JAMA (2002)
Similar primary coronary outcomes across all three agents in 33,357 high-risk hypertensive patients.
Lisinopril
Oral tablet (20mg)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
heart
LisinoprilLisinopril
Long-acting ACE inhibitor with extensive evidence in hypertension, heart failure, post-MI remodeling, and diabetic nephropathy. Cornerstone cardiovascular agent with decades of safety data.
Mortality reduction in HFrEF
Renoprotective (proteinuria reduction)
Post-MI remodeling prevention
Decades of safety data
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
Mechanism of action
Inhibits ACE, blocking conversion of angiotensin I to angiotensin II. Reduces vasoconstriction and aldosterone secretion. Also inhibits bradykinin degradation (contributes to therapeutic effects and cough).
The baseline panel.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Hormone Profile
12 markers
Sex hormones
- Total TestosteroneLC/MS
- Free TestosteroneEquilibrium Dialysis
- Estradiol, Sensitive / UltrasensitiveLC/MS
- Sex Hormone Binding Globulin (SHBG)
- ProgesteroneLC/MSFemale panel
- Prolactin
- Luteinizing Hormone (LH)
- Follicle-Stimulating Hormone (FSH)
- hCG, Total, QuantitativeFemale panel, pre-menopause
Adrenals & neurosteroids
- Cortisol
- DHEA-S
Growth hormone / IGF-1
- Insulin-Like Growth Factor I (IGF-1)
Thyroid Status
3 markers
Thyroid hormones
- Thyroid Stimulating Hormone (TSH)
- Free T4
- Free T3
Heart Health
9 markers
Cardiovascular health
- Total Cholesterol
- HDL Cholesterol
- LDL Cholesterol
- LDL:HDL Ratio
- VLDL Cholesterol
- Triglycerides
- Apolipoprotein-B (ApoB)
- C-Reactive Protein, High Sensitivity (hsCRP)
- Lipoprotein(a) (Lp(a))
Metabolism
3 markers
Insulin sensitivity
- Blood Glucose
- Fasting Insulin
- HbA1c
Organ Function
26 markers
Liver & pancreas
- AST
- ALT
- Bilirubin, Total
- γ-Glutamyl Transferase (GGT)
Kidney function
- BUN
- Creatinine w/ eGFR
Comprehensive Metabolic Panel (CMP)
- Glucose
- Blood Urea Nitrogen (BUN)
- Creatinine
- eGFR
- BUN/Creatinine Ratio
- Sodium
- Potassium
- Chloride
- Carbon Dioxide, Total
- Calcium
- Protein, Total
- Albumin
- Globulin, Total
- Albumin/Globulin (A/G) Ratio
- Alkaline Phosphatase (ALP)
- AST
- ALT
Prostate health
- Prostate-Specific Antigen (PSA)Male panel
- Free PSAMale panel
- % Free PSAMale panel
Nutrient Status
31 markers
Vitamins & minerals
- Vitamin D, 25-OHD (25-Hydroxy)
- Magnesium, RBC
Iron status
- Iron
- Iron Saturation
- TIBC
- UIBC
- Ferritin
Complete Blood Count (CBC)
- White Blood Count (WBC)
- Red Blood Count (RBC)
- Hemoglobin (Hgb)
- Hematocrit (HCT)
- MCV
- MCH
- MCHC
- Red Cell Distribution Width (RDW)
- Platelets
- Neutrophils
- Neutrophils (Absolute)
- Lymphocytes
- Lymphocytes (Absolute)
- Neutrophil/Lymphocyte Ratio
- Monocytes
- Monocytes (Absolute)
- Eosinophils
- Eosinophils (Absolute)
- Basophils
- Basophils (Absolute)
- Immature Cells
- Immature Granulocytes
- Immature Granulocytes (Absolute)
- NRBC, w/ Reflex for Immature Cells
Clinical evidence
The research behind Lisinopril.
Safety profile
Monitoring & safety information.
Commonly reported side effects
- Dry cough (10 to 15%)
- Dizziness
- Headache
- Hyperkalemia
- Elevated creatinine on initiation
Less common but serious risks
- Angioedema (1/1,000 to 5,000; more common in Black patients)
- Severe hyperkalemia
- Fetal toxicity (Category D)
Generally not appropriate for
- Pregnancy
- Prior ACE inhibitor angioedema
- Bilateral renal artery stenosis
- K+ >5.5
Typical monitoring
- Blood pressure
- Serum K+ and Na+
- Renal function (expect mild SCr rise)
- UACR
- Cough/angioedema symptoms
FAQ
Quick answers.
Long-acting ACE inhibitor with extensive evidence in hypertension, heart failure, post-MI remodeling, and diabetic nephropathy. Cornerstone cardiovascular agent with decades of safety data.
Mortality reduction in HFrEF. Renoprotective (proteinuria reduction). Post-MI remodeling prevention. Decades of safety data. Inexpensive.
Common side effects include: dry cough (10 to 15%), dizziness, headache, hyperkalemia, elevated creatinine on initiation. Most side effects are dose-dependent and may resolve with continued use or dose adjustment.
Long-acting ACE inhibitor with extensive evidence in hypertension, heart failure, post-MI remodeling, and diabetic nephropathy. Cornerstone cardiovascular agent with decades of safety data.
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.